{site_meta && site_meta.display_name} Logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

NetworkNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Combines Targeted Cancer Therapy, Nanotechnology and AI

August 5, 2026Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is pursuing an integrated approach to cancer drug development that combines three emerging areas: PNKP-targeted DNA damage response (“DDR”) inhibition, nanoparticle drug delivery and artificial intelligence.


TechMediaBreaks – Why BOXABL Inc. (NASDAQ: BXBL) Is ‘One to Watch’

August 5, 2026BOXABL (NASDAQ: BXBL) was featured in a recent article that discussed its positioning as a technology company focused on transforming residential construction through a factory-built, modular housing system designed for scale. The publication reads, “By shifting homebuilding from traditional on-site processes to controlled manufacturing environments, the company aims to introduce a more standardized, efficient and repeatable approach to housing production.


Why Anthropic’s and OpenAI’s Models Could Have Gone Rogue

August 5, 2026Artificial intelligence is becoming more capable every year, but recent testing incidents involving Anthropic and OpenAI have shown that these powerful systems can also create unexpected cybersecurity risks. During separate testing exercises, AI models from both companies managed to access real companies’ systems, raising concerns about how advanced AI should be developed, tested, and regulated.


Existing Immune Protein May Boost Immunotherapy Against Cancer

August 5, 2026Nagoya University researchers have discovered an ancient protein that occurs naturally in a wide variety of animals and has the potential to make immunotherapy treatments more effective. C3, a protein produced in the liver, typically helps the body fight off infections.


BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Publishes Peer-Reviewed Capture-Seq Study

August 5, 2026VolitionRx Limited (NYSE American: VNRX) announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company said is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (“ctDNA”). According to the publication, the technology addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring.


MissionIRNewsBreaks – SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics

August 4, 2026SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets.